PUBLISHER: Grand View Research | PRODUCT CODE: 1841952
PUBLISHER: Grand View Research | PRODUCT CODE: 1841952
The global AI in radiology market size was estimated at USD 10.57 billion in 2024 and is projected to reach USD 193.02 billion by 2033, growing at a CAGR of 38.12% from 2025 to 2033. Rising demand for accurate and early disease detection, rapid growth in imaging volumes, and government initiatives and regulatory support are significant factors contributing to market growth.
In addition, growing emphasis on cost-efficiency in healthcare delivery and technological advancements in machine learning, natural language processing, and computer vision are some other factors fueling market growth further. The rising demand for accurate and early disease detection is a primary driver of the AI in radiology market. Chronic conditions such as cancer, cardiovascular diseases, and neurological disorders are increasing globally, necessitating advanced imaging tools for early intervention. AI-enabled image analysis enhances diagnostic accuracy by detecting subtle abnormalities that might be missed by human interpretation. Automated quantification and risk stratification further improve diagnostic confidence. These capabilities reduce variability across radiologists and support personalized treatment planning. For instance, in April 2024, Exo launched FDA-cleared AI applications for heart failure diagnosis and lung assessment on its Exo Iris handheld ultrasound device. Thus, as healthcare systems focus on value-based care, the adoption of AI in radiology is becoming essential.
Technological advancements in machine learning, natural language processing, and computer vision fuel the growth of the AI in radiology industry. Deep learning algorithms are improving in accuracy, enabling more reliable interpretation of complex imaging modalities such as CT, MRI, and PET scans. For instance, iPETcertum, developed by Claritas NucMed Technologies, received FDA 510(k) clearance in August 2025. It is an AI-powered software device that enhances PET, PET-CT, and PET-MRI scans by automating the segmentation and quantification of tumors and lesions.
Integration of large language models and generative AI supports advanced clinical decision-making and structured reporting. For instance, in February 2025, RapidAI secured FDA 510(k) clearance for Lumina 3D, an AI-powered, automated 3D imaging reconstruction solution for head and neck CTA. Lumina 3D enables near real-time, high-quality 3D vascular images, reducing manual workflow burdens and improving diagnostic speed, accuracy, and procedural planning for neuroradiologists and neuro-interventionalists. Furthermore, AI tools are increasingly designed to integrate seamlessly with PACS and electronic health record systems. These innovations provide radiologists with actionable insights, creating a more connected and efficient diagnostic ecosystem.
Global AI In Radiology Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global AI in radiology market report based on component, technology, modality, application, end use, and region: